Cytori Therapeutics Inc. said June 11 that it regained compliance with Nasdaq stock market's minimum bid price rule.
Related listing qualification matters have now been closed.
In May, the company implemented a 1-for-10 reverse stock split to regain compliance with the exchange's bid price listing requirement.
San Diego-based Cytori Therapeutics develops cellular therapeutics for specific diseases and medical conditions.
